Novo Holdings would like to congratulate our portfolio company Cyteir Therapeutics on their recent IPO (Nasdaq: CYT). Novo Ventures, the ventures arm of Novo Holdings invested in this company when it was preclinical based on the stellar leadership and the deep scientific insight exploiting synthetic lethality to develop better cancer drugs. We are thrilled to see Cyteir’s wholly owned lead compound, CYT-0851, advancing in the clinic and helping cancer patients.

For further information, please find the full statement here.